Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma

Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies

(2016) Keiji Shinozuka et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas

(2015) Yago Nieto et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Feasibility of Azacitidine Added to Standard Chemotherapy in Older Patients with Acute Myeloid Leukemia — A Randomised SAL Pilot Study

(2013) Utz Krug et al.   PLoS One

High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphoid Malignancies

(2012) Yago Nieto et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

(2012) Yago Nieto et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines

(2012) Benigno C. Valdez et al.   EXPERIMENTAL HEMATOLOGY

Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus

(2012) Michel Meignan et al.   LEUKEMIA & LYMPHOMA

HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL

(2011) M. Kalac et al.   BLOOD

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies

(2010) Partow Kebriaei et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Plasma brain natriuretic peptide is associated with hepatic veno-occlusive disease and early mortality after allogeneic hematopoietic stem cell transplantation

(2010) K Kataoka et al.   BONE MARROW TRANSPLANTATION

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

(2010) Christian Gisselbrecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapy with azanucleosides for myelodysplastic syndromes

(2010) Alfonso Quintás-Cardama et al.   Nature Reviews Clinical Oncology

Identification of a Predictive Biomarker for Hematologic Toxicities of Gemcitabine

(2009) Junichi Matsubara et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukaemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation

(2009) Z.Y. Lim et al.   LEUKEMIA RESEARCH

Pretreatment C-Reactive Protein Is a Predictor for Outcomes after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

(2008) Andrew S. Artz et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION